D
David F. Stojdl
Researcher at Children's Hospital of Eastern Ontario
Publications - 69
Citations - 8877
David F. Stojdl is an academic researcher from Children's Hospital of Eastern Ontario. The author has contributed to research in topics: Oncolytic virus & Virus. The author has an hindex of 30, co-authored 67 publications receiving 8005 citations. Previous affiliations of David F. Stojdl include Ottawa Hospital Research Institute & University of Ottawa.
Papers
More filters
Journal ArticleDOI
An Integrated Stress Response Regulates Amino Acid Metabolism and Resistance to Oxidative Stress
Heather P. Harding,Yuhong Zhang,Huiquing Zeng,Isabel Novoa,Phoebe D. Lu,Marcella Calfon,Navid Sadri,Chi Yun,Brian Popko,Richard S. Paules,David F. Stojdl,John C. Bell,Thore Hettmann,Jeffrey M. Leiden,David Ron +14 more
TL;DR: A signaling pathway initiated by eIF2alpha phosphorylation protects cells against metabolic consequences of ER oxidation by promoting the linked processes of amino acid sufficiency and resistance to oxidative stress.
Journal ArticleDOI
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
David F. Stojdl,Brian D. Lichty,Benjamin R. tenOever,Jennifer M Paterson,Anthony T Power,Shane Knowles,Ricardo Marius,Jennifer Reynard,Laurent Poliquin,Harold L. Atkins,Earl G. Brown,Russell K. Durbin,Joan E. Durbin,John Hiscott,John C. Bell +14 more
TL;DR: Evidence is presented that the attenuated vesicular stomatitis strains, AV1 and AV2, embody all of the traits of an oncolytic virus, which will replicate preferentially in malignant cells, have the ability to treat disseminated metastases, and ultimately be cleared by the patient.
Journal ArticleDOI
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.
David F. Stojdl,Brian D. Lichty,Shane Knowles,Ricardo Marius,Harold L. Atkins,Nahum Sonenberg,John C. Bell +6 more
TL;DR: Vesicular stomatitis virus (VSV), an enveloped, negative-sense RNA virus exquisitely sensitive to treatment with interferon, is used as a replication-competent oncolytic virus and a new strategy for the treatment of interferons non-responsive tumors is demonstrated.
Journal ArticleDOI
Going viral with cancer immunotherapy
TL;DR: The ability to engineer OVs that express immune-stimulating 'cargo', the induction of immunogenic tumour cell death by OVs and the selective targeting of OVs to tumour beds suggests that they are the ideal reagents to enhance antitumour immune responses.
Journal ArticleDOI
Vesicular stomatitis virus: re-inventing the bullet
TL;DR: Strains of VSV that induce or direct the production of interferon are superior to wild-type strains of the virus for inducing oncolysis and might also make better vaccine vectors.